Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease
Standard
Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. / Wang, Wei-Lin Winnie; Sorokin, Igor; Aleksic, Ilija; Fisher, Hugh; Kaufman, Ronald P; Winer, Andrew; McNeill, Brian; Gupta, Raavi; Tilki, Derya; Fleshner, Neil; Klotz, Laurence; DiRienzo, A Gregory; Tenniswood, Martin.
In: J UROLOGY, Vol. 204, No. 3, 09.2020, p. 466-475.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease
AU - Wang, Wei-Lin Winnie
AU - Sorokin, Igor
AU - Aleksic, Ilija
AU - Fisher, Hugh
AU - Kaufman, Ronald P
AU - Winer, Andrew
AU - McNeill, Brian
AU - Gupta, Raavi
AU - Tilki, Derya
AU - Fleshner, Neil
AU - Klotz, Laurence
AU - DiRienzo, A Gregory
AU - Tenniswood, Martin
PY - 2020/9
Y1 - 2020/9
N2 - PURPOSE: This is the first report of the development and performance of a platform that interrogates small noncoding RNAs (sncRNA) isolated from urinary exosomes. The Sentinel™ PCa Test classifies patients with prostate cancer from subjects with no evidence of prostate cancer, the miR Sentinel CS Test stratifies patients with prostate cancer between those with low risk prostate cancer (Grade Group 1) from those with intermediate and high risk disease (Grade Group 2-5), and the miR Sentinel HG Test stratifies patients with prostate cancer between those with low and favorable intermediate risk prostate cancer (Grade Group 1 or 2) and those with high risk (Grade Group 3-5) disease.MATERIALS AND METHODS: sncRNAs were extracted from urinary exosomes of 235 participants and interrogated on miR 4.0 microarrays. Using proprietary selection and classification algorithms, informative sncRNAs were selected to customize an interrogation OpenArray™ platform that forms the basis of the tests. The tests were validated using a case-control sample of 1,436 subjects.RESULTS: The performance of the miR Sentinel PCa Test demonstrated a sensitivity of 94% and specificity of 92%. The Sentinel CS Test demonstrated a sensitivity of 93% and specificity of 90% for prediction of the presence of Grade Group 2 or greater cancer, and the Sentinel HG Test demonstrated a sensitivity of 94% and specificity of 96% for the prediction of the presence of Grade Group 3 or greater cancer.CONCLUSIONS: The Sentinel PCa, CS and HG Tests demonstrated high levels of sensitivity and specificity, highlighting the utility of interrogation of urinary exosomal sncRNAs for noninvasively diagnosing and classifying prostate cancer with high precision.
AB - PURPOSE: This is the first report of the development and performance of a platform that interrogates small noncoding RNAs (sncRNA) isolated from urinary exosomes. The Sentinel™ PCa Test classifies patients with prostate cancer from subjects with no evidence of prostate cancer, the miR Sentinel CS Test stratifies patients with prostate cancer between those with low risk prostate cancer (Grade Group 1) from those with intermediate and high risk disease (Grade Group 2-5), and the miR Sentinel HG Test stratifies patients with prostate cancer between those with low and favorable intermediate risk prostate cancer (Grade Group 1 or 2) and those with high risk (Grade Group 3-5) disease.MATERIALS AND METHODS: sncRNAs were extracted from urinary exosomes of 235 participants and interrogated on miR 4.0 microarrays. Using proprietary selection and classification algorithms, informative sncRNAs were selected to customize an interrogation OpenArray™ platform that forms the basis of the tests. The tests were validated using a case-control sample of 1,436 subjects.RESULTS: The performance of the miR Sentinel PCa Test demonstrated a sensitivity of 94% and specificity of 92%. The Sentinel CS Test demonstrated a sensitivity of 93% and specificity of 90% for prediction of the presence of Grade Group 2 or greater cancer, and the Sentinel HG Test demonstrated a sensitivity of 94% and specificity of 96% for the prediction of the presence of Grade Group 3 or greater cancer.CONCLUSIONS: The Sentinel PCa, CS and HG Tests demonstrated high levels of sensitivity and specificity, highlighting the utility of interrogation of urinary exosomal sncRNAs for noninvasively diagnosing and classifying prostate cancer with high precision.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Algorithms
KW - Biomarkers, Tumor/metabolism
KW - Case-Control Studies
KW - Exosomes/metabolism
KW - Humans
KW - Male
KW - Middle Aged
KW - Prostatic Neoplasms/metabolism
KW - RNA, Small Untranslated/metabolism
KW - Sensitivity and Specificity
U2 - 10.1097/JU.0000000000001020
DO - 10.1097/JU.0000000000001020
M3 - SCORING: Journal article
C2 - 32191585
VL - 204
SP - 466
EP - 475
JO - J UROLOGY
JF - J UROLOGY
SN - 0022-5347
IS - 3
ER -